Skip to main content
Archives of Disease in Childhood logoLink to Archives of Disease in Childhood
. 1997 Oct;77(4):299–304. doi: 10.1136/adc.77.4.299

Usefulness of antinuclear antibody testing to screen for rheumatic diseases

P Malleson 1, M Sailer 1, M Mackinnon 1
PMCID: PMC1717342  PMID: 9389231

Abstract





OBJECTIVE—To assess the usefulness of the indirect immunofluorescence antinuclear antibody test (FANA) using human laryngeal epithelial carcinoma cells as nuclear substrate, to screen for childhood rheumatic diseases.
STUDY DESIGN—A review of all FANA tests performed on children at British Columbia's Children's Hospital between 7 March 1991 and 31 July 1995.
RESULTS—FANA tests were positive at titres of 1:20 or greater in 41% of all subjects tested, and in 65% of all subjects in whom the diagnosis was obtained. FANA positivity occurred in 67% of those with a rheumatic disease, compared with 64% of those with a non-rheumatic disease (p=0.4). More girls had high titre FANA positivity than boys independent of whether or not they had a rheumatic disease (p=0.05). At a screening serum dilution of 1:40 a positive test has a sensitivity of only 0.63, and a positive predictive value of only 0.33 for any rheumatic disease. For systemic lupus erythematosus (SLE), mixed connective tissue disease (MCTD), or overlap syndrome at a screening dilution of 1:40 the test has a very high sensitivity of 0.98, but a very low positive predictive value of only 0.10,the test having slightly better characteristics for boys than girls.
CONCLUSION—Although a negative FANA test makes a diagnosis of SLE or MCTD extremely unlikely, a positive test even at moderately high titres of 1:160 or higher is found so frequently in children without a rheumatic disease that a positive result has little or no diagnostic value. It is suggested that a screening serum dilution of 1:160 or 1:320 would increase the usefulness of the test, by decreasing false positive tests, without significantly increasing false negative tests for SLE or MCTD, and would have the potential for considerable cost savings.



Full Text

The Full Text of this article is available as a PDF (110.3 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Arroyave C. M., Giambrone M. J., Rich K. C., Walaszek M. The frequency of antinuclear antibody (ANA) in children by use of mouse kidney (MK) and human epithelial cells (HEp-2) as substrates. J Allergy Clin Immunol. 1988 Nov;82(5 Pt 1):741–744. doi: 10.1016/0091-6749(88)90073-5. [DOI] [PubMed] [Google Scholar]
  2. Cabral D. A., Petty R. E., Fung M., Malleson P. N. Persistent antinuclear antibodies in children without identifiable inflammatory rheumatic or autoimmune disease. Pediatrics. 1992 Mar;89(3):441–444. [PubMed] [Google Scholar]
  3. Chudwin D. S., Ammann A. J., Cowan M. J., Wara D. W. Significance of a positive antinuclear antibody test in a pediatric population. Am J Dis Child. 1983 Nov;137(11):1103–1106. doi: 10.1001/archpedi.1983.02140370063021. [DOI] [PubMed] [Google Scholar]
  4. Deane P. M., Liard G., Siegel D. M., Baum J. The outcome of children referred to a pediatric rheumatology clinic with a positive antinuclear antibody test but without an autoimmune disease. Pediatrics. 1995 Jun;95(6):892–895. [PubMed] [Google Scholar]
  5. Hanley J. A., McNeil B. J. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology. 1982 Apr;143(1):29–36. doi: 10.1148/radiology.143.1.7063747. [DOI] [PubMed] [Google Scholar]
  6. Haynes D. C., Gershwin M. E., Robbins D. L., Miller J. J., 3rd, Cosca D. Autoantibody profiles in juvenile arthritis. J Rheumatol. 1986 Apr;13(2):358–363. [PubMed] [Google Scholar]
  7. Malleson P. N., Fung M. Y., Rosenberg A. M. The incidence of pediatric rheumatic diseases: results from the Canadian Pediatric Rheumatology Association Disease Registry. J Rheumatol. 1996 Nov;23(11):1981–1987. [PubMed] [Google Scholar]
  8. Montecucco C., Ravelli A., Caporali R., Viola S., De Gennaro F., Albani S., Martini A. Autoantibodies in juvenile dermatomyositis. Clin Exp Rheumatol. 1990 Mar-Apr;8(2):193–196. [PubMed] [Google Scholar]
  9. Tan E. M., Cohen A. S., Fries J. F., Masi A. T., McShane D. J., Rothfield N. F., Schaller J. G., Talal N., Winchester R. J. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982 Nov;25(11):1271–1277. doi: 10.1002/art.1780251101. [DOI] [PubMed] [Google Scholar]

Articles from Archives of Disease in Childhood are provided here courtesy of BMJ Publishing Group

RESOURCES